Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis-Reference-Cited by-同舟云学术

Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis

Published:2018-03-23 Issue:5 Volume:36 Page:939-948
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Kasuga Akiyoshi^ORCID,Hamamoto Yasuo,Takeuchi Ayano,Okano Naohiro,Togasaki Kazuhiro,Aoki Yu,Suzuki Takeshi,Kawasaki Kenta,Hirata Kenro,Sukawa Yasutaka,Kanai Takanori,Takaishi Hiromasa

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/article/10.1007/s10637-018-0589-6/fulltext.html

Reference40 articles.

1. Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E (2017) European cancer mortality predictions for the year 2017, with focus on lung cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO 28(5):1117–1123. https://doi.org/10.1093/annonc/mdx033

2. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332

3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. https://doi.org/10.3322/caac.20107

4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703. https://doi.org/10.1056/NEJMoa1304369

5. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (19):1817–1825. doi: https://doi.org/10.1056/NEJMoa1011923

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer;Internal Medicine;2022-12-15

2. The application of the Glasgow prognostic score to predict the survival in patients with metastatic pancreatic carcinoma;Indian Journal of Palliative Care;2022-07-25

3. Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer;International Journal of Molecular Sciences;2022-01-21

4. Surrogate Endpoints in Oncology: Overview of Systematic Reviews and Their Use for Health Decision Making in Mexico;Value in Health Regional Issues;2021-12

5. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework;Health Technology Assessment;2021-12